Date: 2018-01-22
Type of information: Private placement
Company: Beigene (China)
Investors:
Amount: $800 million
Funding type: private placement
Planned used:
- BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.
Others:
- • On January 22, 2018, BeiGene announced the closing of its follow-on public offering of 7,920,800 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS, for gross proceeds of approximately $800 million before deducting underwriting discounts and commissions and other offering expenses. This includes the full exercise of the underwriters’ option to purchase an additional 495,050 ADSs.
- • On January 17, 2018, BeiGene announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS. The gross proceeds to BeiGene from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $750 million. In addition, BeiGene has granted the underwriters a 30-day option to purchase up to an additional 495,050 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 22, 2018, subject to customary closing conditions.
- • On January 16, 2018, BeiGene announced a public offering of its American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share. BeiGene intends to offer and sell $650 million of its ADSs, before underwriting discounts and commissions and estimated offering expenses. Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners are acting as joint book-running managers.
- The securities described above are being offered pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).
Therapeutic area: Cancer - Oncology
Is general: Yes
